Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ss-IR recombinant antigen
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Ss-IR (Strongyloides stercoralis immunoreactive antigen) recombinant antigen is an experimental recombinant protein subunit vaccine antigen derived from the parasitic nematode *Strongyloides stercoralis*. Produced in *Escherichia coli*, Ss-IR has been investigated as a prophylactic vaccine candidate against human strongyloidiasis. In preclinical mouse models, immunization with Ss-IR in combination with an alum adjuvant induces a robust antibody-dependent immune response, significantly reducing larval survival upon challenge. Additionally, Ss-IR is utilized as a highly sensitive and specific serodiagnostic antigen in multiplex bead assays and ELISA platforms (such as the Strongy Detect ELISA developed by InBios) to detect *S. stercoralis* infections and prevent life-threatening hyperinfection syndrome in immunocompromised individuals.
- Other names
- rSsIRSs-IRStrongyloides stercoralis immunoreactive antigen
Beyond the preview
Go deeper on Ss-IR recombinant antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ss-IR recombinant antigen.